Windsor Creek Advisors’s Aldeyra Therapeutics ALDX Stock Holding History

Windsor Creek Advisors’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-16,500	Closed	-$196K	–	171
2021 Q1	$196K	Sell	16,500 -9,080	-35%	-$105K	0.05%	163
2020 Q4	$175K	Buy	25,580 +5,000	+24%	+$35.1K	0.04%	176
2020 Q3	$152K	Buy	+20,580	New	+$133K	0.04%	163

Other funds holding ALDX

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Windsor Creek Advisors's ALDX Position: Q2 2021 in Review

Windsor Creek Advisors sold out of Aldeyra Therapeutics (ALDX) in Q2 2021, closing a stake of 16,500 shares — an estimated $196K sold.

Windsor Creek Advisors first reported a position in ALDX in Q3 2020 and held it in 3 quarters. The position peaked at $196K in Q1 2021. 136 funds tracked by Wall St. Rank hold ALDX as of Q2 2021.

Windsor Creek Advisors reported no remaining Aldeyra Therapeutics position as of Q2 2021 after selling out during the quarter.
Windsor Creek Advisors sold 16,500 Aldeyra Therapeutics shares in Q2 2021, an estimated $196K.
Windsor Creek Advisors first reported a position in Aldeyra Therapeutics in Q3 2020 and held it in 3 quarters.
Windsor Creek Advisors's Aldeyra Therapeutics position peaked at $196K in Q1 2021.
136 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2021.

Based on Windsor Creek Advisors's 13F filing for Q2 2021, filed 5 Aug 2021.